Characterizing the viral and host effector mechanisms that govern HIV-1 rebound
表征控制 HIV-1 反弹的病毒和宿主效应机制
基本信息
- 批准号:10629260
- 负责人:
- 金额:$ 81.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-25 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAftercareAnimal ModelBindingBiodiversityBiologicalBiologyBloodBlood TestsBrainCD4 Positive T LymphocytesCRISPR screenCellsChronicClinicalDataDisease remissionFrequenciesGenesGoalsHIV-1HIV/AIDSHost Defense MechanismHumanImmuneImmune responseIndividualInfectionIntegration Host FactorsInterferonsInterruptionKineticsKnowledgeLymphLymphoid TissueMacaca mulattaMacrophageMapsMethodsMicrogliaMinorityMolecular CloningMyeloid CellsParticipantPathway interactionsPhenotypePlasmaPropertyProvirusesRecrudescencesResearchResistanceSamplingSiteSourceTestingThoracic DuctTimeTissuesTranslatingTropismVariantViralViral GenesViral reservoirViremiaVirusWomanantiretroviral therapyclinically relevantcohortcytokinedesignimprovedin vivoinsightknockout genelymphatic ductmalenovel strategiespressurepreventreactivation from latencyrecruitresponsesimian human immunodeficiency virusviral rebound
项目摘要
PROJECT SUMMARY
A central goal in HIV/AIDS cure research is preventing or delaying viral rebound following analytical treatment
interruption (ATI). It is widely assumed that understanding the viral and host factors involved in in vivo latency
reactivation would lead to new, more rational cure strategies; however, the biology and provenance of the
rebounding virus remains largely unknown. Here, we propose to leverage four recent discoveries from our
groups to gain insight into the mechanisms of HIV-1 recrudescence. Using “gold standard” sampling methods
to characterize the latent reservoir before and after treatment interruption (ATI), we discovered that viral isolates
derived by quantitative virus outgrowth (QVOA) do not represent or predict the viruses that emerge in the plasma
following treatment interruption (1, 2). We also found that rebound viruses, but not QVOA-derived reservoir
viruses, were highly resistant to type 1 interferons (IFN-I), indicating potent host innate responses at the site of
viral recrudescence (3). Surprisingly, some, but not all, rebound
suggesting
isolates replicated to high titers in macrophages,
a greater biological diversity than previously known. Finally, we discovered that IFN-I resistant
rebound viruses have the ability to reseed the reservoir, raising the possibility of long-term clinical consequences
of ATI (2, 3). In this application, we will leverage these discoveries to elucidate the viral and host factors
that govern HIV-1 rebound. Our hypothesis is that by (i) determining the universality, kinetics and clinical
impact of IFN-I resistance during rebound, (ii) defining the viral determinants of IFN-I resistance and the host
interferon stimulated genes (ISGs) that place pressure on the rebounding virus, and (iii) tracing the provenance
of IFN-I resistant rebound viruses, we will uncover key mechanisms that control HIV-1 reactivation from latency.
In Aim 1, we will expand our studies to more diverse ATI trial participants, including women, minorities, acute
and early ART initiators and individuals receiving IFN-I modulating therapies, to assess the generality of the
IFN-I resistant phenotype of rebound viruses. We will also test to what extent IFN-I resistance persists during
prolonged ATI and determine how this influences the rates of IFN-I resistant viruses that reseed the reservoir. In
Aim 2, we will elucidate the biological properties of rebound HIV-1, map the viral determinants of IFN-I resistance,
and identify the host interferon stimulated genes (ISGs) that place pressure on the recrudescing virus. In Aim 3,
we will trace the provenance of rebound virus by testing blood, thoracic duct lymph and lymphatic tissue using
regular and modified QVOAs, examine whether long-lived myeloid cells, including brain macrophages and
microglia, serve as reservoirs of IFN-I resistant viruses, and explore whether SHIV-infected rhesus macaques
recapitulate the IFN-I phenotypes of HIV-1 reservoir and rebound viruses. We expect these studies to improve
our understanding of the clinically relevant, rebound competent HIV-1 reservoir, the mechanisms underlying in
vivo viral reactivation and the host factors that place pressure on the rebounding virus pool, which should lead
to more rational and effective HIV/AIDS cure strategies.
.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katharine June Bar其他文献
Katharine June Bar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katharine June Bar', 18)}}的其他基金
Determining the effects of broadly neutralizing antibodies at antiretroviral therapy initiation
确定广泛中和抗体在抗逆转录病毒治疗开始时的作用
- 批准号:
10772448 - 财政年份:2023
- 资助金额:
$ 81.25万 - 项目类别:
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1
补充广泛中和抗体和自体反应,以限制病毒逃逸并持久抑制 HIV-1
- 批准号:
10469169 - 财政年份:2022
- 资助金额:
$ 81.25万 - 项目类别:
Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1
补充广泛中和抗体和自体反应,以限制病毒逃逸并持久抑制 HIV-1
- 批准号:
10608215 - 财政年份:2022
- 资助金额:
$ 81.25万 - 项目类别:
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound
表征控制 HIV-1 反弹的病毒和宿主效应机制
- 批准号:
10437036 - 财政年份:2021
- 资助金额:
$ 81.25万 - 项目类别:
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing
用于评估 CRISPR/Cas9 基因编辑的新型巨噬细胞嗜性传播/中枢神经系统持久性 SHIV 模型
- 批准号:
10331568 - 财政年份:2021
- 资助金额:
$ 81.25万 - 项目类别:
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing
用于评估 CRISPR/Cas9 基因编辑的新型巨噬细胞嗜性传播/中枢神经系统持久性 SHIV 模型
- 批准号:
10443900 - 财政年份:2021
- 资助金额:
$ 81.25万 - 项目类别:
Novel macrophage-tropic transmitted/founder SHIV model of CNS persistence to evaluate CRISPR/Cas9 gene editing
用于评估 CRISPR/Cas9 基因编辑的新型巨噬细胞嗜性传播/中枢神经系统持久性 SHIV 模型
- 批准号:
10606618 - 财政年份:2021
- 资助金额:
$ 81.25万 - 项目类别:
Characterizing the viral and host effector mechanisms that govern HIV-1 rebound
表征控制 HIV-1 反弹的病毒和宿主效应机制
- 批准号:
10332623 - 财政年份:2021
- 资助金额:
$ 81.25万 - 项目类别:
Immunological Strategies to Modulate SIV Rebound Following ART Interruption
ART 中断后调节 SIV 反弹的免疫策略
- 批准号:
10224003 - 财政年份:2017
- 资助金额:
$ 81.25万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 81.25万 - 项目类别:
Research Grant